OBJECTIVE: The Treatment of Early Age @entity162 (TEAM) study evaluated @entity1091 , @entity1090 , and @entity1092 ( @entity1092 ) in @entity1 with @entity162 who were naive to antimanic medication, or were partial or nonresponders to 1 of 3 study medications. This report evaluates the benefit of either an add-on or a switch of antimanic medications for an 8-week trial period in partial responders and nonresponders, respectively. METHOD: TEAM is a randomized, controlled trial of individuals (N  = 379) aged 6 to 15 years (mean    SD  = 10.2    2.7 years) with DSM-IV @entity162 (mixed or @entity162 phase). @entity1 (n  = 154) in this report were either nonresponders or partial responders to 1 of the 3  study medications. Nonresponders (n  = 89) were randomly assigned to 1 of the other 2 antimanic medications and cross-tapered. Partial responders (n  = 65) were randomly assigned to 1 of 2 other antimanic medications as an add-on to their initial medication. Adverse event (AE) rates are reported only for the add-on group. RESULTS: Response rate for @entity1 switched to @entity1090 (47.6%) was higher than for those switched to either  @entity1091 (12.8%; p  = .005; number needed to treat [NNT]  = 3; 95% CI  =  1.71-9.09) or @entity1092 (17.2%; p  =  .03; NNT  = 3; 95% CI  = 1.79-20.10); response rate for partial responders who added @entity1090 (53.3%) was higher than for those who added @entity1092 (0%; p  =  .0002; NNT  = 2; 95% CI  = 1.27-3.56) and trended higher for @entity1091 (26.7%; p  = .07; NNT  = 4). Reported AEs in the add-on group were largely consistent with the known AE profile for the second medication. @entity1017 (kg) was observed for all add-on medications: @entity1091 add-on (n  =  29 of 30)  = 1.66    1.97; @entity1090 add-on (n  = 15 of 15)  = 2.8    1.34; @entity1092 add-on (n  = 19 of 20)  = 1.42    1.96. There was no evidence at the 5% significance level that the average @entity1017 was different by study medication for partial responders (p  =  .07, 1-way analysis of variance). CONCLUSION: @entity1090 appears to be more useful than @entity1091 or @entity1092 for @entity1 with @entity162 and other comorbid conditions who are nonresponders or partial responders to an initial antimanic medication trial. Clinical trial registration information-Study of Outcome and Safety of @entity1091 , @entity1092 and @entity1090 for @entity162 in @entity1 and Adolescents (TEAM); http://clinicaltrials.gov/; NCT00057681.

Treatment of Early-Age XXXX : Outcomes for Partial and Nonresponders to Initial Treatment.

@entity1 :: ('9606', 'Species') :: ['children', 'Children', 'Participants'] @entity162 :: ('MESH:D001714', 'Disease') :: ['manic', 'bipolar I disorder', 'Mania'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Divalproex', 'divalproex', 'divalproex sodium'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['Weight gain', 'weight gain'] @entity1091 :: ('MESH:D008094', 'Chemical') :: ['Lithium', 'lithium'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone', 'Risperidone']
@entity162 :: (MESH:D001714,Disease) :: ['Mania']
